Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.

J Headache Pain · 2018 · PMC6755578 · PMID 30225735

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

a strong trendP = 0.052so close (0.05 < p ≤ 0.1)

Likewise, the mean number of monthly days with peak headache intensity of more than 4 in a 1–10 numerical scale (moderate / severe pain) was also changed between T1 and T3 with a strong trend to significance towards further reduction (3.4 ± 2.8– range: 0–14 vs 2.5 ± 1.1 – range: 1–5; P = 0.052).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.